From CNBC: 2024-04-25 00:01:01

Walgreens plans to work directly with drugmakers to bring cell and gene therapies to U.S. patients, expanding their specialty pharmacy services. They are launching a new business unit dedicated to specialty pharmacy with AllianceRx subsidiary. The move comes as specialty pharmacies play a crucial role in treating chronic diseases like cancer and Crohn’s disease.

The company is investing in a licensed facility in Pittsburgh dedicated to cell and gene therapies. The FDA has approved seven cell and gene therapies last year, with expectations of reviewing and approving 10 to 20 annually by 2025. Walgreens’ new business unit is the largest independent provider of specialty pharmacy services, generating around $24 billion in revenue.

Walgreens’ specialty pharmacies offer counseling, financial assistance, and services like injection training and side-effect management. With over 1,500 specialty pharmacists and access to 240 limited distribution drugs, Walgreens aims to provide patients with expert care and resources for a smooth treatment experience.



Read more at CNBC: Walgreens launches cell, gene therapies in service expansion